Short answer: Topical estriol is a weak oestrogen used locally for genitourinary symptoms of menopause — vulvovaginal atrophy, vaginal dryness and recurrent urinary tract infections — at strengths typically from 0.005% to 0.1% in a cream or gel base. For prescribers in Kuala Lumpur, a compounded estriol cream allows individualised strength and vehicle selection when commercial products are unavailable or a patient-specific formulation is required, prepared as a non-sterile cream for a named patient on a doctor’s prescription under Good Compounding Practice (GCP).
When to consider topical estriol versus systemic routes
Estriol is the weakest of the three naturally occurring oestrogens, and its clinical role in menopause management is predominantly local — addressing the genitourinary symptoms of menopause (GSM) rather than systemic vasomotor symptoms. For prescribers deciding between topical and systemic oestrogen, the distinction matters because topical estriol at low doses achieves local tissue effect with minimal systemic exposure, whereas systemic hormone therapy (oral or transdermal estradiol) addresses vasomotor symptoms and bone health but carries a different systemic safety profile.
Indications where topical estriol is appropriate
The evidence base for topical estriol centres on vulvovaginal atrophy and its sequelae. A phase III randomised controlled trial of 0.005% estriol vaginal gel demonstrated efficacy for symptoms and signs of postmenopausal vaginal atrophy (Cano et al., Menopause, 2012; PMID 22914208). A randomised controlled trial of ultra-low-dose 0.005% estriol vaginal gel in postmenopausal women with genitourinary syndrome of menopause confirmed its role in reducing recurrent urinary tract infections (Muiños et al., Maturitas, 2024; PMID 39388913). A clinical trial of local ultra-low-dose estriol gel for vulvo-vaginal atrophy reported long-term efficacy and safety over extended treatment duration (Villa et al., Gynecological Endocrinology, 2020; PMID 31847628).
For breast cancer survivors on aromatase inhibitors — a population for whom systemic oestrogen is typically contraindicated — a phase II randomised controlled trial of 0.005% estriol vaginal gel demonstrated efficacy for vulvovaginal atrophy without raising serum estradiol levels into the range that would contraindicate its use (Hirschberg et al., Menopause, 2020; PMID 32049923). A systematic review and meta-analysis of hormonal treatments for vulvovaginal atrophy in breast cancer survivors examined the safety profile of topical estriol in this population, reporting that serum estradiol levels remained within acceptable ranges for local low-dose preparations (Comini et al., Clinical Breast Cancer, 2023; PMID 37806915).
A randomised controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections demonstrated a reduction in recurrence over the study period (Raz et al., New England Journal of Medicine, 1993; PMID 8350884). A randomised controlled trial of low-dose intravaginal estriol for urogenital ageing in postmenopausal women confirmed local efficacy for urogenital symptoms (Dessole et al., Menopause, 2004; PMID 14716182).
When systemic therapy is preferred
Topical estriol does not address vasomotor symptoms (hot flushes, night sweats), bone density, or mood changes associated with menopause. Where these symptoms predominate, systemic oestrogen therapy — oral or transdermal estradiol, typically with a progestogen for women with an intact uterus — remains the appropriate route. Topical estriol is an option when the clinical need is local, when systemic therapy is contraindicated, or when a patient prefers local treatment for isolated genitourinary symptoms.
Contraindications and interactions
Topical estriol is generally contraindicated in undiagnosed vaginal bleeding, known or suspected oestrogen-dependent malignancy (without specialist input), active or history of venous thromboembolism, and pregnancy. For breast cancer survivors, the decision requires oncology input — the evidence supports low-dose topical estriol’s minimal systemic absorption, but each case is individual. Drug interactions are minimal at topical doses, but prescribers should review concurrent systemic hormone therapies to avoid cumulative oestrogen load.
Vehicle and strength selection for compounded estriol
Evidence-based strengths
The published evidence for topical estriol in GSM centres on ultra-low-dose formulations, most studied at 0.005% in a vaginal gel. A pharmacokinetic study of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women characterised the absorption profile and confirmed that systemic exposure at this dose is minimal (Delgado et al., Climacteric, 2016; PMID 26786399). A study of systemic bioavailability following repeated vaginal administration of 0.03 mg estriol pessaries confirmed that even at low doses, a fraction of estriol reaches the systemic circulation, which is relevant for patients on concurrent therapies (Buhling et al., Arzneimittel-Forschung, 2012; PMID 22692777).
For compounded preparations, the prescriber specifies the strength. The evidence supports a range from 0.005% (ultra-low-dose, matching the studied vaginal gel) to 0.1% (a higher concentration used in some compounded formulations). The choice depends on symptom severity, the prescriber’s clinical assessment, and the patient’s individual risk profile. A compounded preparation allows the prescriber to specify a strength outside the fixed commercial options, individualised to the patient.
Cream versus gel
The published evidence for topical estriol is primarily in vaginal gel formulations. A cream base is the more common vehicle for compounded preparations, and the choice between cream and gel depends on the application site, the patient’s preference, and the prescriber’s clinical intent. A randomised controlled trial comparing fractional microablative radiofrequency with topical estriol for genitourinary syndrome of menopause used topical estriol as the comparator, confirming its role as a standard local treatment (Torre et al., International Journal of Gynaecology and Obstetrics, 2026; PMID 41065268).
A randomised controlled trial of ultra-low-dose topical estriol in postmenopausal women who underwent surgical treatment for pelvic organ prolapse examined vaginal health and quality-of-life outcomes, supporting the use of topical estriol in the post-surgical context (Caruso et al., Menopause, 2017; PMID 28350758).
For compounded preparations, the vehicle is not an inert carrier — it governs how much active is released and how the patient applies it. A compounding pharmacy prepares estriol in a cream or gel base at the strength the prescriber specifies. The choice of vehicle is a clinical and pharmaceutical decision: the prescriber specifies the base, and the pharmacy prepares it to specification under GCP.
Dosing examples and monitoring plan
Baseline assessment
Before initiating topical estriol, the prescriber should document:
- Menopausal status and symptom assessment (vaginal dryness, dyspareunia, urinary symptoms)
- Breast and gynaecological screening up to date
- Blood pressure, weight and BMI
- Serum estradiol if clinically indicated (particularly in breast cancer survivors)
- Concurrent medications, especially systemic hormone therapies
- Contraindications review (VTE history, oestrogen-dependent malignancy, undiagnosed bleeding)
Typical dosing and follow-up
The studied dosing for ultra-low-dose vaginal estriol gel is 0.005% applied once daily for two to three weeks, then reduced to a maintenance schedule of one to three times weekly. For compounded preparations, the prescriber sets the strength, frequency and duration based on the clinical assessment. Follow-up at four to six weeks allows assessment of symptom response and local tolerance. For breast cancer survivors, serum estradiol monitoring at baseline and follow-up is warranted, as the Hirschberg trial demonstrated the importance of confirming that local therapy does not elevate systemic estradiol (Hirschberg et al., Menopause, 2020; PMID 32049923).
Red flags
Prescribers should advise patients to report any vaginal bleeding, breast changes, or signs of thromboembolism. Persistent symptoms despite adequate dosing and duration warrant reassessment of the diagnosis and treatment approach. Any change in systemic hormone therapy status requires a review of the topical estriol regimen.
GCP and documentation checklist for the prescriber
Every compounded preparation requires a named-patient prescription and a formulation brief. The prescriber’s checklist for compounding referrals — covering the prescription, formulation brief, GCP compliance and review plan — applies to every compounded preparation, including topical estriol. The prescription should include:
- Patient name (named-patient compounding)
- Active ingredient: estriol
- Strength (e.g. 0.005%, 0.01%, 0.1% — as clinically indicated)
- Dosage form (cream or gel)
- Vehicle preference, if specified
- Application instructions and frequency
- Prescriber’s signature and date
The formulation brief should include the clinical rationale (GSM, VVA, breast cancer survivor on AI therapy), the anatomical site of application, any known excipient sensitivities, and the review plan. The pharmacy prepares the formulation under Good Compounding Practice (GCP) on a prescription-only basis. A certificate of analysis for the estriol active ingredient should be requested from the compounding pharmacy for each batch.
Patient counselling and regulatory notes for KL expats
Expatriate patients arriving in Kuala Lumpur with an overseas prescription for topical estriol should be aware that the specific product they used abroad may not be registered or stocked in Malaysia. A local GP or gynaecologist can assess the patient and issue a Malaysian prescription for a compounded preparation at the appropriate strength and in the preferred vehicle. Importing hormone preparations into Malaysia is subject to regulatory controls, and patients should not rely on personal importation as a long-term supply strategy.
For patients transitioning from an overseas prescriber, the counselling points are:
- Bring medical records, recent hormone panels and the previous prescription to the first Malaysian appointment
- The compounded preparation is made for one named patient — it is not a commercial product and cannot be transferred
- Application technique and frequency should be reviewed at the first follow-up
- Storage conditions for the compounded cream or gel should be confirmed with the pharmacy
- Any change in systemic therapy or new symptoms should be reported to the prescriber
Discussing a compounded estriol preparation with Lynnity
Lynnity prepares non-sterile compounded creams on a named-patient prescription basis under Good Compounding Practice (GCP). For a compounded estriol preparation, the prescriber specifies the active ingredient, strength and dosage form in the prescription, and may include a formulation brief covering the vehicle preference and anatomical site. For prescribers considering bioidentical hormone therapy more broadly, Lynnity also prepares compounded bioidentical progesterone in capsule, cream or liquid form on prescription. To start a referral, the prescriber writes a named-patient prescription with the active, strength and dosage form, includes a brief clinical rationale, and confirms the formulation details with the pharmacy.
Frequently asked questions
What strength of topical estriol is typically used for genitourinary symptoms of menopause?
The most studied strength is 0.005% estriol in a vaginal gel, supported by phase III and long-term safety data. Compounded preparations may be prescribed at strengths from 0.005% to 0.1% depending on the clinical assessment. The prescriber sets the strength based on symptom severity, the patient’s risk profile, and the intended application site.
Is topical estriol safe for breast cancer survivors?
A phase II randomised controlled trial of 0.005% estriol vaginal gel in breast cancer survivors on aromatase inhibitors demonstrated local efficacy without raising serum estradiol into the contraindicated range (Hirschberg et al., Menopause, 2020; PMID 32049923). A systematic review and meta-analysis confirmed that topical low-dose estriol preparations maintain serum estradiol within acceptable limits in this population (Comini et al., Clinical Breast Cancer, 2023; PMID 37806915). Oncology input is required for each individual case.
How is a compounded estriol cream prescribed in Malaysia?
A compounded estriol cream requires a named-patient prescription from a registered doctor specifying the active ingredient, strength, dosage form and application instructions. The prescription is sent to a non-sterile compounding pharmacy that prepares the formulation under Good Compounding Practice (GCP). The prescriber may include a formulation brief with the clinical rationale, vehicle preference and review plan.
What monitoring is needed for patients using topical estriol?
Baseline assessment includes symptom evaluation, breast and gynaecological screening, and serum estradiol where clinically indicated. Follow-up at four to six weeks assesses symptom response and local tolerance. For breast cancer survivors, serum estradiol monitoring is warranted to confirm that local therapy does not elevate systemic levels. Patients should report any vaginal bleeding, breast changes or thromboembolic signs.
Can an expat patient use an overseas prescription for compounded estriol in Kuala Lumpur?
An overseas prescription is not directly fillable by a Malaysian compounding pharmacy. The patient should consult a local GP or gynaecologist in Kuala Lumpur, who can assess the clinical need and issue a Malaysian prescription for a compounded preparation at the appropriate strength. Importing hormone preparations into Malaysia is subject to regulatory controls, and personal importation is not a reliable long-term supply strategy.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632)
To discuss a patient-specific compounded estriol preparation, consult Lynnity’s compounding pharmacists, including Lead Pharmacist Vitthia Rama Murti, RPh (RPh 15632), at the compounding facility in MWE Commercial Park, Kepong, Kuala Lumpur.